Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Hepatitis B Treatment Market: By Drug Class, By Route of Administration, By Distribution Channel and Region Forecast 2019-2030
Hepatitis B Treatment Market size was valued at US$ 548.84 million in 2023, and is poised to grow at a CAGR of 10.3% from 2024-2030. Hepatitis-B is also known as serum hepatitis which is an infectious disease of the liver caused by the Hepatitis-B virus (HBV). Hepatitis B is classified into two types namely, acute and chronic kidney disease (ckd) drugs. In this condition, the virus interferes with the hepatocytes and the liver becomes inflamed.
Hepatitis B is commonly caused through parenteral contacts such as blood, body fluids, and sexual intercourse. The Hepatitis B virus is unable to cross the skin or mucous membranes. People with Lymph proliferative disease, Acquired Immuno Deficiency Syndrome (AIDS), and people treated with immunosuppressant drugs and hemodialysis patients easily develop an infection with the Hepatitis-B Virus. The symptoms of Hepatitis B do not develop until after a few weeks of exposure. The severity of Hepatitis may cause cirrhosis, liver failure, and hepatocellular carcinoma (HCC). A vaccine is commonly administered to protect people from the infection. Hepatitis B can be prevented by administering the hepatitis B vaccine to newborn babies, avoiding promiscuity and not having multiple sexual partners, and avoiding sharing of injections and razors can also prevent the Hepatitis B infection.
Geographically, the market is in the growing stage, as various government organizations are initiating awareness programs to prevent hepatitis B infection. An increase in the prevalence of hepatitis B infection and liver cirrhosis might fuel the market. According to the World Health Organization, there are currently 240 million chronic carriers of the hepatitis B virus of which approximately 1525% of carriers will develop cirrhosis, hepatocellular carcinoma (HCC), or liver decompensation, and 780,000 will die each year as a result of their infection. Acquisitions and mergers, collaborations, launching of new products, increase in research and development activities, and approvals for new products from various drug regulatory bodies such as the U.S. Food and Drug Administration are some strategies followed by various companies to increase their share in the global market.
For instance, in September 2013, Roche and Inovio Pharmaceuticals collaborated on research, development, and commercialization of Inovio's highly optimized, multi-antigen DNA immunotherapies targeting hepatitis B and prostate cancer. Similarly, in July 2015, Benitec Biopharma and Biomics Biotechnologies announced that Benitec has acquired the full rights to the pre-clinical ddRNAi-based hepatitis B (HBV) therapeutic program, Hepbarna, which was previously under development as a joint venture between the two companies. In addition, Moreover, various drugs for hepatitis B treatment in the pipeline are also expected to propel the hepatitis B treatment industry over the forecast period.
Study Period
2024-2030Base Year
2023CAGR
10.3%Largest Market
North AmericaFastest Growing Market
Asia Pacific
The market is expected to grow at a significant CAGR due to increase in the prevalence of Hepatitis B infection. According to the World Health Organization (WHO), chronic hepatitis B virus infection occurs in majority of the infants. Rising awareness regarding hepatitis B treatment, increase in the healthcare expenditure, rise in the funding in research and development activities for hepatitis B treatment, and various pipeline products for Hepatitis B treatment might fuel the global market over the forecast period. However, high cost of the hepatitis B treatment and medications, less effectiveness of antiviral drugs against hepatitis B infection might hamper the growth of global market over the forecast period.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2023 |
US$ 548.84 million |
Market CAGR |
10.3% |
By Drug Class |
|
By Route of Administration |
|
By Distribution Channel |
|
By Region |
|
Download Free Sample Report
The Hepatitis B Treatment Market size was estimated at US$ 548.84 million in 2023, growing at a CAGR of 10.3% from 2024 - 2030.
The market key players are: F. Hoffmann- La Roche Ltd. (Switzerland) and GlaxoSmithKline, plc. (U.K.) Bristol-Myers Squibb (U.S) Novartis AG (Switzerland) Merck and Co Inc., (U.S) Novira Therapeutics Inc. (U.S.) Johnson & Johnson Services Inc., (U.S.) Inovio Pharmaceuticals Inc. (U.S.) Benitec biopharma Ltd. (Australia) Gilead Sciences (U.S.) Cipla Inc. (India) Biomics biotechnologies (China)
The market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
1. Executive Summary |
2. Global Hepatitis B Treatment Market Introduction |
2.1.Global Hepatitis B Treatment Market - Taxonomy |
2.2.Global Hepatitis B Treatment Market - Definitions |
2.2.1.Drug Class |
2.2.2.Route of Administration |
2.2.3.Distribution Channel |
2.2.4.Region |
3. Global Hepatitis B Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4. Global Hepatitis B Treatment Market Analysis, 2019-2023 and Forecast 2024-2030 |
4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Hepatitis B Treatment Market By Drug Class, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
5.1. Chemo Therapy |
5.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Immunosuppressant |
5.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Nucleoside Analogue |
5.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
6. Global Hepatitis B Treatment Market By Route of Administration, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
6.1. Oral |
6.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Parenteral |
6.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Others |
6.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7.Global Hepatitis B Treatment Market By Distribution Channel, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
7.1. Hospital Pharmacies |
7.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Retail Pharmacies |
7.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Others |
7.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8.Global Hepatitis B Treatment Market By Region, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9. North America Hepatitis B Treatment Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
9.1. Drug Class Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Chemo Therapy |
9.1.2.Immunosuppressant |
9.1.3.Nucleoside Analogue |
9.2. Route of Administration Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Oral |
9.2.2.Parenteral |
9.2.3.Others |
9.3. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospital Pharmacies |
9.3.2.Retail Pharmacies |
9.3.3.Others |
9.4. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Hepatitis B Treatment Market,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
10.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Chemo Therapy |
10.1.2.Immunosuppressant |
10.1.3.Nucleoside Analogue |
10.2. Route of Administration Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Oral |
10.2.2.Parenteral |
10.2.3.Others |
10.3. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospital Pharmacies |
10.3.2.Retail Pharmacies |
10.3.3.Others |
10.4. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
10.4.6.Rest of EU |
11. Asia Pacific (APAC) Hepatitis B Treatment Market,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
11.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Chemo Therapy |
11.1.2.Immunosuppressant |
11.1.3.Nucleoside Analogue |
11.2. Route of Administration Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Oral |
11.2.2.Parenteral |
11.2.3.Others |
11.3. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospital Pharmacies |
11.3.2.Retail Pharmacies |
11.3.3.Others |
11.4. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Hepatitis B Treatment Market,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
12.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Chemo Therapy |
12.1.2.Immunosuppressant |
12.1.3.Nucleoside Analogue |
12.2. Route of Administration Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Oral |
12.2.2.Parenteral |
12.2.3.Others |
12.3. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospital Pharmacies |
12.3.2.Retail Pharmacies |
12.3.3.Others |
12.4. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13. Latin America Hepatitis B Treatment Market,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
13.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Chemo Therapy |
13.1.2.Immunosuppressant |
13.1.3.Nucleoside Analogue |
13.2. Route of Administration Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Oral |
13.2.2.Parenteral |
13.2.3.Others |
13.3. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospital Pharmacies |
13.3.2.Retail Pharmacies |
13.3.3.Others |
13.4. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.F. Hoffmann- La Roche Ltd. (Switzerland) |
14.2.2.GlaxoSmithKline, plc. (U.K.) |
14.2.3.Bristol-Myers Squibb (U.S) |
14.2.4.Novartis AG (Switzerland) |
14.2.5.Merck and Co Inc., (U.S) |
14.2.6.Novira Therapeutics Inc. (U.S.) |
14.2.7.Johnson & Johnson Services Inc., (U.S.) |
14.2.8.Inovio Pharmaceuticals Inc. (U.S.) |
14.2.9.Benitec biopharma Ltd. (Australia) |
14.2.10.Gilead Sciences (U.S.) |
14.2.11.Cipla Inc. (India) |
14.2.12.Biomics biotechnologies (China) |
15. Research Methodology |
16. Appendix and Abbreviations |
Key Market Players